Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies.

Abstract:

:Glycosylation is a critical attribute for development and manufacturing of therapeutic monoclonal antibodies (mAbs) in the pharmaceutical industry. Conventional antibody glycan analysis is usually achieved by the 2-aminobenzamide (2-AB) hydrophilic interaction liquid chromatography (HILIC) method following the release of glycans. Although this method produces satisfactory results, it has limited use for screening a large number of samples because it requires expensive reagents and takes several hours or even days for the sample preparation. A simple and rapid glycan analysis method was not available. To overcome these constraints, we developed and compared 2 ultrafast methods for antibody glycan analysis (UMAG) that involve the rapid generation and purification of glycopeptides in either organic solvent or aqueous buffer followed by label-free quantification using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Both methods quickly yield N-glycan profiles of test antibodies similar to those obtained by the 2-AB HILIC-HPLC method. In addition, the UMAG method performed in aqueous buffer has a shorter assay time of less than 15 min, and enables high throughput analysis in 96-well PCR plates with minimal sample handling. This method, the fastest, and simplest as reported thus far, has been evaluated for glycoprofiling of mAbs expressed under various cell culture conditions, as well as for the evaluation of antibody culture clones and various production batches. Importantly the method sensitively captured changes in glycoprofiles detected by traditional 2-AB HILIC-HPLC or HILIC-UPLC. The simplicity, high speed, and low cost of this method may facilitate basic research and process development for novel mAbs and biosimilar products.

journal_name

MAbs

journal_title

mAbs

authors

Yang X,Kim SM,Ruzanski R,Chen Y,Moses S,Ling WL,Li X,Wang SC,Li H,Ambrogelly A,Richardson D,Shameem M

doi

10.1080/19420862.2016.1156828

subject

Has Abstract

pub_date

2016-05-01 00:00:00

pages

706-17

issue

4

eissn

1942-0862

issn

1942-0870

journal_volume

8

pub_type

杂志文章

相关文献

mAbs文献大全
  • Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies.

    abstract::Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1755069

    authors: Scott MJ,Jowett A,Orecchia M,Ertl P,Ouro-Gnao L,Ticehurst J,Gower D,Yates J,Poulton K,Harris C,Mullin MJ,Smith KJ,Lewis AP,Barton N,Washburn ML,de Wildt R

    更新日期:2020-01-01 00:00:00

  • Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.

    abstract::Optimization of biophysical properties is a critical success factor for the developability of monoclonal antibodies with potential therapeutic applications. The inter-domain disulfide bond between light chain (Lc) and heavy chain (Hc) in human IgG1 lends structural support for antibody scaffold stability, optimal anti...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.24291

    authors: Shen Y,Zeng L,Zhu A,Blanc T,Patel D,Pennello A,Bari A,Ng S,Persaud K,Kang YK,Balderes P,Surguladze D,Hindi S,Zhou Q,Ludwig DL,Snavely M

    更新日期:2013-05-01 00:00:00

  • Immunotherapy for Alzheimer disease.

    abstract::Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque path...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.2.7829

    authors: Gouras GK

    更新日期:2009-03-01 00:00:00

  • High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer.

    abstract::The Fc glycosylation of therapeutic antibodies is crucial for their effector functions and their behavior in pharmacokinetics and pharmacodynamics. To monitor the Fc glycosylation in bioprocess development and characterization,high-throughput techniques for glycosylation analysis are needed. Here, we describe the deve...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.26712

    authors: Reusch D,Haberger M,Kailich T,Heidenreich AK,Kampe M,Bulau P,Wuhrer M

    更新日期:2014-01-01 00:00:00

  • High throughput detection of antibody self-interaction by bio-layer interferometry.

    abstract::Self-interaction of an antibody may lead to aggregation, low solubility or high viscosity. Rapid identification of highly developable leads remains challenging, even though progress has been made with the introduction of techniques such as self-interaction chromatography (SIC) and cross-interaction chromatography (CIC...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.26186

    authors: Sun T,Reid F,Liu Y,Cao Y,Estep P,Nauman C,Xu Y

    更新日期:2013-11-01 00:00:00

  • Certolizumab pegol.

    abstract::Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pe...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.2.11271

    authors: Goel N,Stephens S

    更新日期:2010-03-01 00:00:00

  • American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.

    abstract::The American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference Short Course "Translational Challenges in Developing Antibody-Drug Conjugates (ADCs)," held May 24, 2012 in San Diego, CA, was organized by members of the Pharmacokinetics, Pharmacodynamics and Drug Metabolism section of AAP...

    journal_title:mAbs

    pub_type:

    doi:10.4161/mabs.22909

    authors: Thudium K,Bilic S,Leipold D,Mallet W,Kaur S,Meibohm B,Erickson H,Tibbitts J,Zhao H,Gupta M

    更新日期:2013-01-01 00:00:00

  • Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.

    abstract::The current standard treatment for acute myeloid leukemia (AML) is chemotherapy based on cytarabine and daunorubicine (7 + 3), but it discriminates poorly between malignant and benign cells. Dose-limiting off‑target effects and intrinsic drug resistance result in the inefficient eradication of leukemic blast cells and...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1007818

    authors: Fitting J,Blume T,Ten Haaf A,Blau W,Gattenlöhner S,Tur MK,Barth S

    更新日期:2015-01-01 00:00:00

  • Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system.

    abstract::We describe protein synthesis, folding and assembly of antibody fragments and full-length aglycosylated antibodies using an Escherichia coli-based open cell-free synthesis (OCFS) system. We use DNA template design and high throughput screening at microliter scale to rapidly optimize production of single-chain Fv (scFv...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.4.2.19202

    authors: Yin G,Garces ED,Yang J,Zhang J,Tran C,Steiner AR,Roos C,Bajad S,Hudak S,Penta K,Zawada J,Pollitt S,Murray CJ

    更新日期:2012-03-01 00:00:00

  • A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis.

    abstract::Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specif...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1714371

    authors: Murer P,Plüss L,Neri D

    更新日期:2020-01-01 00:00:00

  • Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies.

    abstract::The plasticity of natural immunoglobulin repertoires can be exploited for the generation of phage display libraries. Secondary lymphoid organs, such as the spleen and the lymph nodes, constitute interesting sources of diversity because they are rich in B cells, part of which can be affinity matured. These organs, howe...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25592

    authors: Venet S,Kosco-Vilbois M,Fischer N

    更新日期:2013-09-01 00:00:00

  • Antibody-drug conjugate library prepared by scanning insertion of the aldehyde tag into IgG1 constant regions.

    abstract::The advantages of site-specific over stochastic bioconjugation technologies include homogeneity of product, minimal perturbation of protein structure/function, and - increasingly - the ability to perform structure activity relationship studies at the conjugate level. When selecting the optimal location for site-specif...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1512327

    authors: Huang BCB,Kim YC,Bañas S,Barfield RM,Drake PM,Rupniewski I,Haskins WE,Rabuka D

    更新日期:2018-11-01 00:00:00

  • Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

    abstract::MPDL3280A is a human monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1), and exerts anti-tumor activity mainly by blocking PD-L1 interaction with programmed cell death-1 (PD-1) and B7.1. It is being investigated as a potential therapy for locally advanced or metastatic malignancies. The purpose ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1136043

    authors: Deng R,Bumbaca D,Pastuskovas CV,Boswell CA,West D,Cowan KJ,Chiu H,McBride J,Johnson C,Xin Y,Koeppen H,Leabman M,Iyer S

    更新日期:2016-01-01 00:00:00

  • Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

    abstract::CD4(+) CD25(+) regulatory T cells are expanded in solid and hematological malignancies including chronic lymphocytic leukemia (CLL). Several cytokines and co-stimulatory molecules are required for generation, survival and maintenance of their suppressive effect. We and others have shown direct cytotoxic effect of the ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.1.10561

    authors: Gowda A,Ramanunni A,Cheney C,Rozewski D,Kindsvogel W,Lehman A,Jarjoura D,Caligiuri M,Byrd JC,Muthusamy N

    更新日期:2010-01-01 00:00:00

  • Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.

    abstract::Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite significantly enhanced homogeneity, however, the production of site-specific ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1624127

    authors: Cao M,De Mel N,Jiao Y,Howard J,Parthemore C,Korman S,Thompson C,Wendeler M,Liu D

    更新日期:2019-08-01 00:00:00

  • Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

    abstract::Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25439

    authors: Challa DK,Bussmeyer U,Khan T,Montoyo HP,Bansal P,Ober RJ,Ward ES

    更新日期:2013-09-01 00:00:00

  • A method to confer Protein L binding ability to any antibody fragment.

    abstract::Recombinant antibody single-chain variable fragments (scFv) are difficult to purify homogeneously from a protein complex mixture. The most effective, specific and fastest method of purification is an affinity chromatography on Protein L (PpL) matrix. This protein is a multi-domain bacterial surface protein that is abl...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1116657

    authors: Lakhrif Z,Pugnière M,Henriquet C,di Tommaso A,Dimier-Poisson I,Billiald P,Juste MO,Aubrey N

    更新日期:2016-01-01 00:00:00

  • Antibody adsorption on the surface of water studied by neutron reflection.

    abstract::Surface and interfacial adsorption of antibody molecules could cause structural unfolding and desorbed molecules could trigger solution aggregation, resulting in the compromise of physical stability. Although antibody adsorption is important and its relevance to many mechanistic processes has been proposed, few techni...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1276141

    authors: Smith C,Li Z,Holman R,Pan F,Campbell RA,Campana M,Li P,Webster JR,Bishop S,Narwal R,Uddin S,van der Walle CF,Lu JR

    更新日期:2017-04-01 00:00:00

  • The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.

    abstract::Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the pot...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1016692

    authors: Brady LJ,Velayudhan J,Visone DB,Daugherty KC,Bartron JL,Coon M,Cornwall C,Hinckley PJ,Connell-Crowley L

    更新日期:2015-01-01 00:00:00

  • Evaluating imbalances of adverse events during biosimilar development.

    abstract::Biosimilars are designed to be highly similar to approved or licensed (reference) biologics and are evaluated based on the totality of evidence from extensive analytical, nonclinical and clinical studies. As part of the stepwise approach recommended by regulatory agencies, the first step in the clinical evaluation of ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1171431

    authors: Vana AM,Freyman AW,Reich SD,Yin D,Li R,Anderson S,Jacobs IA,Zacharchuk CM,Ewesuedo R

    更新日期:2016-07-01 00:00:00

  • Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteins.

    abstract::Gel microdroplet - fluorescence activated cell sorting (GMD-FACS) is an innovative high throughput screening platform for recombinant protein libraries, and we show here that GMD-FACS can overcome many of the limitations associated with conventional screening methods for antibody libraries. For example, phage and cell...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2017.1381812

    authors: Fang Y,Chu TH,Ackerman ME,Griswold KE

    更新日期:2017-11-01 00:00:00

  • Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities.

    abstract::Antibodies provide immune protection by recognizing antigens of diverse chemical properties, but elucidating the amino acid sequence-function relationships underlying the specificity and affinity of antibody-antigen interactions remains challenging. We designed and constructed phage-displayed synthetic antibody librar...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1550320

    authors: Jian JW,Chen HS,Chiu YK,Peng HP,Tung CP,Chen IC,Yu CM,Tsou YL,Kuo WY,Hsu HJ,Yang AS

    更新日期:2019-02-01 00:00:00

  • Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.

    abstract::Monoclonal antibody (mAb) candidates from high-throughput screening or binding affinity optimization often contain mutations leading to liabilities for further development of the antibody, such as aggregation-prone regions and lack of solubility. In this work, we optimized a candidate integrin α11-binding mAb for deve...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1475871

    authors: Jetha A,Thorsteinson N,Jmeian Y,Jeganathan A,Giblin P,Fransson J

    更新日期:2018-08-01 00:00:00

  • Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

    abstract::Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of thes...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1494105

    authors: Satta A,Mezzanzanica D,Caroli F,Frigerio B,Di Nicola M,Kontermann RE,Iacovelli F,Desideri A,Anichini A,Canevari S,Gianni AM,Figini M

    更新日期:2018-10-01 00:00:00

  • Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach.

    abstract::Monoclonal antibodies (mAbs) against human proteins are the primary protein capture reagents for basic research, diagnosis, and molecular therapeutics. The 2 most important attributes of mAbs used in all of these applications are their specificity and avidity. While specificity of a mAb raised against a human protein ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/19420862.2014.985919

    authors: Liu S,Zhang H,Dai J,Hu S,Pino I,Eichinger DJ,Lyu H,Zhu H

    更新日期:2015-01-01 00:00:00

  • Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest.

    abstract::While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to th...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28257

    authors: Derfus GE,Dizon-Maspat J,Broddrick JT,Velayo AC,Toschi JD,Santuray RT,Hsu SK,Winter CM,Krishnan R,Amanullah A

    更新日期:2014-05-01 00:00:00

  • Cell culture processes for monoclonal antibody production.

    abstract::Animal cell culture technology has advanced significantly over the last few decades and is now generally considered a reliable, robust and relatively mature technology. A range of biotherapeutics are currently synthesized using cell culture methods in large scale manufacturing facilities that produce products for both...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.5.12720

    authors: Li F,Vijayasankaran N,Shen AY,Kiss R,Amanullah A

    更新日期:2010-09-01 00:00:00

  • Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

    abstract::Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxicities that may be d...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2016.1156829

    authors: Donaghy H

    更新日期:2016-05-01 00:00:00

  • Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.

    abstract::Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term 'developability' encompasses the feasibility of molecules to successfully progress from discovery to development via evaluation of their physicochemical properties. These properties includ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1743053

    authors: Bailly M,Mieczkowski C,Juan V,Metwally E,Tomazela D,Baker J,Uchida M,Kofman E,Raoufi F,Motlagh S,Yu Y,Park J,Raghava S,Welsh J,Rauscher M,Raghunathan G,Hsieh M,Chen YL,Nguyen HT,Nguyen N,Cipriano D,Fayadat-Dilma

    更新日期:2020-01-01 00:00:00

  • Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

    abstract::The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27-28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cy...

    journal_title:mAbs

    pub_type:

    doi:10.1080/19420862.2017.1412130

    authors: Martin C,Kizlik-Masson C,Pèlegrin A,Watier H,Viaud-Massuard MC,Joubert N

    更新日期:2018-02-01 00:00:00